Alvotech Files Annual Report with the SEC

Rhea-AI Summary

Alvotech (NASDAQ: ALVO) filed its Annual Report 2025 on Form 20-F with the U.S. Securities and Exchange Commission on March 30, 2026. The filing incorporates parts of the Alvotech Annual Report 2025 and is publicly available on the SEC website and Alvotech investor relations site.

For investor or media inquiries, Alvotech provided contact emails for media and investor relations on its investor site.

Market Reality Check

Price: $3.29 Vol: Volume 722,301 is close t...

normal vol

$3.29 Last Close

Volume Volume 722,301 is close to 20-day average 675,719 (relative 1.07x). normal

Technical Price $3.29 trades below 200-day MA at $6.63 and is 72.24% below the 52-week high of $11.85, only 8.58% above the 52-week low of $3.03.

Peers on Argus

ALVO gained 5.79% while peers were mixed: ANIP up 1.11%, SUPN, BHC, HCM, and IND...

ALVO gained 5.79% while peers were mixed: ANIP up 1.11%, SUPN, BHC, HCM, and INDV down between 0.59% and 1.22%, suggesting a stock-specific move rather than a sector-wide rotation.

Historical Context

5 past events · Latest: Mar 18 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 18	Earnings results	Positive	-5.8%	Q4 and FY 2025 revenue and EBITDA growth with reaffirmed 2026 guidance.
Mar 04	Earnings scheduling	Neutral	+2.4%	Announcement of dates for Q4 and full-year 2025 results and conference call.
Feb 26	Insider share transfer	Neutral	-4.1%	Disclosure of intra‑group transfer of 2,701,617 shares at USD 4.74.
Feb 11	Share capital change	Neutral	-6.7%	Issuance of 12,500,000 shares to subsidiary, increasing total issued share count.
Feb 05	Clinical results	Positive	-2.0%	Positive pivotal PK study results for AVT80 biosimilar to Entyvio.

Pattern Detected

Recent history shows frequent negative price reactions, even to operationally positive or neutral news.

Recent Company History

Over the past few months, Alvotech reported strong FY 2025 results, with revenue and adjusted EBITDA growth and reaffirmed 2026 guidance on Mar 18, 2026, yet the stock fell 5.79%. Earlier announcements included an earnings call scheduling on Mar 4, 2026, intra‑group share transfers on Feb 26, 2026, an increase in own shares on Feb 11, 2026, and positive top-line PK data for AVT80 on Feb 5, 2026. These events often saw negative or muted price moves, contrasting with today’s strong reaction to a routine annual report filing.

Market Pulse Summary

This announcement centers on Alvotech’s filing of its 2025 Annual Report on Form 20-F with the U.S. ...

Analysis

This announcement centers on Alvotech’s filing of its 2025 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission, making detailed financials and disclosures accessible to investors. In light of recent history—earnings growth, clinical milestones, share capital changes, and leadership updates—this filing consolidates prior information into a formal regulatory document. Investors may focus on trends highlighted in the report and how they relate to the stock’s position near its 52-week low of $3.03 and below its 200-day moving average of $6.63.

Key Terms

form 20-f, u.s. securities and exchange commission

2 terms

form 20-f regulatory

"has filed its Annual Report 2025 on Form 20-F for the financial year 2025"

Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.

u.s. securities and exchange commission regulatory

"with the U.S. Securities and Exchange Commission (SEC), incorporating by reference"

The U.S. Securities and Exchange Commission is a government agency responsible for overseeing the stock market and protecting investors. It sets rules to ensure that companies share truthful information and that trading is fair, helping to maintain trust in the financial system. This oversight is important because it helps prevent fraud and ensures that investors can make informed decisions.

AI-generated analysis. Not financial advice.

REYKJAVIK, Iceland, March 30, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) (the “Company”) has filed its Annual Report 2025 on Form 20-F for the financial year 2025 with the U.S. Securities and Exchange Commission (SEC), incorporating by reference parts of the Alvotech Annual Report 2025. The report is available on the SEC’s website, www.sec.gov, as well as in the investor relations section of Alvotech’s website at https://investors.alvotech.com/financials.

For further information, contact:

Media
Benedikt Stefansson
Sarah MacLeod
alvotech.media@alvotech.com

Investors
Dr. Balaji V Prasad (US)
Patrik Ling (SE)
Benedikt Stefansson (IS)
alvotech.ir@alvotech.com

About Alvotech
Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in biosimilars by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira^® (adalimumab), Stelara^® (ustekinumab), Simponi^® (golimumab), Eylea^® (aflibercept) and Prolia^®/Xgeva^® (denosumab). The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.

For more information, please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram and YouTube.

FAQ

What did Alvotech (ALVO) file with the SEC on March 30, 2026?

Alvotech filed its Annual Report 2025 on Form 20-F with the SEC on March 30, 2026. According to Alvotech, the filing incorporates parts of the Alvotech Annual Report 2025 and is available on the SEC and company investor websites for review.

Where can investors access Alvotech (ALVO) Annual Report 2025 Form 20-F?

The Annual Report 2025 Form 20-F is available on the SEC website and Alvotech's investor relations site. According to Alvotech, the report can be accessed at www.sec.gov and https://investors.alvotech.com/financials for download and review.

Does the Alvotech (ALVO) SEC filing include the Annual Report 2025?

Yes, the Form 20-F filing incorporates parts of the Alvotech Annual Report 2025 by reference. According to Alvotech, investors should consult the incorporated Annual Report sections via the SEC filing or the company's investor relations pages.

Who should investors contact for questions about Alvotech (ALVO) Annual Report 2025?

Investors can contact Alvotech investor relations via the provided email addresses listed on the investor relations site. According to Alvotech, specific contacts include Dr. Balaji V Prasad, Patrik Ling, and Benedikt Stefansson at the posted investor relations email.

When did Alvotech (ALVO) announce the filing of its Annual Report 2025 on Form 20-F?

Alvotech announced the Form 20-F filing on March 30, 2026. According to Alvotech, the filing covers the financial year 2025 and is available immediately on both the SEC and Alvotech investor relations websites for public access.